DJIA 17,776.12 -200.19 -1.11%
NASDAQ 4,900.89 -46.56 -0.94%
S&P 500 2,067.89 -18.35 -0.88%
market minute promo

MannKind Corp (NASDAQ: MNKD)

5.20 -0.13 (-2.44%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

MNKD $5.20 -2.44%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.31
Previous Close $5.33
Daily Range $5.18 - $5.33
52-Week Range $3.80 - $11.48
Market Cap $2.1B
P/E Ratio -10.45
Dividend (Yield) $0.00 (0.0%)
Volume 2,264,808
Average Daily Volume 5,195,292
Current FY EPS -$0.34




Drug Makers

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website:

News & Commentary Rss Feed

Investors' Love/Hate Relationship with MannKind Corp. Stock

Emotions run high when it comes to this biotech.

The Unwinding Of Convertible Notes Has Positive Implications For MannKind

MannKind Valuation Scenarios

Afrezza Could Be Sanofi And MannKind's Goose That Laid The Golden Egg

MannKind Stock Approaching Pre-FDA Approval Price: Is A Bottom Coming?

Major Biotech Is So-So for Short Sellers

Analyst: MannKind Afrezza Estimates Are Being Changed 'Based On Physician Feedback'

Early Adopters Embrace Afrezza, As New Inhaled Insulin Enters Market

Did Researchers Just Unlock a Type 1 Diabetes Cure?

Forget just trying to treat the symptoms of type 1 diabetes! According to the findings from this latest study, a type 1 diabetes cure may be possible.

Confessions of a Value Investor Stuck in a High-Growth Industry

It's OK to buy premium-priced biotechs.

See More MNKD News...

MNKD's Top Competitors

MNKD $5.20 (-2.44%)
Current stock: MNKD
AMGN $159.85 (-2.71%)
Current stock: AMGN
GILD $98.13 (-2.54%)
Current stock: GILD
BIIB $422.24 (-2.17%)
Current stock: BIIB